The cost of antiretroviral drugs and influence on prescribing policies.
With the advent of highly active antiretroviral therapy (HAART), the prognosis for HIV-infected individuals with access has been transformed. HAART provides one of the most cost-effective treatments for any chronic disease. Immediate cost remains a legitimate factor when choosing HAART regimens, however, the cost of long-term side-effects and adherence issues must also be considered. The review examines the cost issues associated with HAART prescription and its influence on prescribing policies.
Jones
Rachael
R
Department of HIV and GU Medicine, The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. rachael.jones@chelwest.nhs.uk
Gazzard
Brian
B
D044966:Anti-Retroviral Agents / Q000191:economics* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics*; D016527:Drug Costs; D004363:Drug Utilization / Q000191:economics; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics; D006801:Humans; D010818:Practice Patterns, Physicians'
D044966:Anti-Retroviral Agents